C2N Diagnostics Reports Phase 1 Study Results of C2N-8E12 (ABBV-8E12) – Anti-Tau Antibody – in Subjects with Progressive Supranuclear Palsy

  • Clinical Investigator, Dr. Diana Kerwin, Presents Safety, Tolerability and PK Data at CTAD 2016 in Late-Breaking Oral Session
  • Results Demonstrate that ABBV-8E12 is Safe and Well Tolerated at Doses up to 50 mg/kg in Subjects with Progressive Supranuclear Palsy
  • Results are Guiding the Design of Phase 2 Studies in Subjects with Alzheimer’s Disease and Progressive Supranuclear Palsy

December 09, 2016

ST. LOUIS, MO – C2N Diagnostics today reported results from its Phase 1 study testing ABBV-8E12 (Formerly C2N-8E12) in patients with progressive supranuclear palsy (PSP). ABBV-8E12 is a humanized anti-tau monoclonal antibody currently under clinical investigation for the treatment of Alzheimer’s Disease and PSP, both progressive brain diseases currently lacking effective treatment options. Results from the first-in-human study were reported …
Read More →

C2N Diagnostics Completes Phase 1 Clinical Study of C2N-8E12 (ABBV-8E12) Among Individuals with Progressive Supranuclear Palsy

  • Achievement Represents the Final Milestone Under C2N’s “Part the Cloud” 2015 Translational Research Award from Alzheimer’s Association
  • Paves Way for Future, Longer-Term Clinical Studies Involving ABBV-8E12 Through Partnership with AbbVie

October 13, 2016

ST. LOUIS, MO – C2N Diagnostics today announced that it has successfully completed the final follow-up visit of the last subject enrolled into its Phase 1, randomized controlled clinical study testing C2N-8E12 (ABBV-8E12), an anti-tau antibody, in patients with progressive supranuclear palsy (PSP). The milestone marks the last of multiple achievements under C2N’s Part the Cloud (PTC) Translational Research Award, granted to C2N by the Alzheimer’s Association in 2015. Also, this is an important program milestone under …
Read More →

CurePSP Forms Subsidiary to Promote Clinical Trials

CurePSP has formed the new Patient Engagement Program (PEP) to help speed recruitment of eligible participants for industry-sponsored clinical trials, with the goal of finding treatments for degenerative brain diseases. Agreements have been reached with Bristol-Myers Squibb and AbbVie.

Read the press release.…
Read More →

C2N and AbbVie Announce FDA Orphan Drug Designation of C2N-8E12 (ABBV-8E12) for the Treatment of Progressive Supranuclear Palsy

– Initiates Phase 1 clinical study in patients with progressive supranuclear palsy

– Investigational recombinant anti-tau antibody represents lead clinical candidate in global C2N-AbbVie collaboration to address serious brain disorders

NORTH CHICAGO, Ill., July 17, 2015 /PRNewswire/ — C2N Diagnostics and AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted their investigational recombinant humanized anti-tau antibody, C2N-8E12 (ABBV-8E12), an orphan drug designation for the treatment of progressive supranuclear palsy (PSP). The companies also have begun a Phase 1 clinical study of C2N-8E12 in patients with PSP.

“The FDA’s orphan drug designation recognizes the lack of treatment options for patients with PSP, a debilitating neurological disease, and is …
Read More →